2E9 Stock Chart & Stats
€0.08
<€0.01(11.11%)
At close: 4:00 PM EDT
€0.08
<€0.01(11.11%)
Day’s Range― - ―
52-Week Range€0.01 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€26.99M
Enterprise Value€317.65M
Total Cash (Recent Filing)€127.64M
Total Debt (Recent Filing)€866.00K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 12, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€1.92M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageA near-zero debt burden reduces interest and refinancing pressure, giving Intervacc greater flexibility to manage development and commercialization spending. This conservative capital structure can help the company withstand operating volatility while it works toward improving product economics.
Substantial Equity BaseA substantial equity position provides financial runway for a biotech business that is still investing ahead of sustainable profitability. Although it does not eliminate funding needs, this capital base can support continued operations and product commercialization without heavy reliance on debt.
Commercialized Canine VaccineHaving a marketed canine vaccine gives Intervacc an established commercial platform rather than relying solely on pre-revenue research. Continued adoption through veterinary clinics and distributors could provide a foundation for recurring product sales and future animal-health expansion.
Bears Say
Persistent UnprofitabilityNegative gross profit and substantial operating losses show that current product economics do not yet cover the cost base. Without a durable improvement in pricing, volume, or operating efficiency, continued losses can consume capital and delay the transition to self-funded growth.
Ongoing Cash BurnPersistent operating and free-cash-flow deficits mean Intervacc is not yet generating the cash needed to fund its business internally. Continued burn increases dependence on its existing liquidity or future financing, potentially constraining investment and creating dilution pressure.
Weak Revenue And Margin TrajectoryThe latest trailing period combines declining revenue with deeply negative gross profit and operating earnings, indicating that earlier growth has not yet become a sustained earnings model. This weak trajectory could limit the company’s ability to scale commercialization profitably over the next several quarters.
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €26.99M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Nov 12, 2026 which is in 31 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on Aug 20, 2026. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of -€0.004 by >-€0.001.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is >-0.01.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.005 in its last earnings report, missing expectations of -€0.004. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
ExpreS2ion Biotech Holding AB
―
Immunicum AB
―
Cantargia AB
―